STERIS (NYSE:STE) Issues FY 2026 Earnings Guidance

STERIS (NYSE:STE) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 10.150-10.30 for the period, compared to the consensus earnings per share estimate of 10.130. The company issued revenue guidance of -, compared to the consensus revenue estimate of $5.9 billion.

STERIS Trading Up 1.0%

Shares of STE traded up $2.69 during mid-day trading on Friday, hitting $262.75. The company had a trading volume of 425,211 shares, compared to its average volume of 597,530. The stock has a market cap of $25.88 billion, a PE ratio of 40.26 and a beta of 1.02. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. The business’s 50-day simple moving average is $243.60 and its 200-day simple moving average is $238.58. STERIS has a 1-year low of $200.98 and a 1-year high of $265.56.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.09. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. During the same period in the prior year, the firm earned $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Sell-side analysts forecast that STERIS will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Tuesday, November 18th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Tuesday, November 18th. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s dividend payout ratio (DPR) is currently 38.59%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on STE shares. KeyCorp lifted their price target on STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a report on Tuesday, July 22nd. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Morgan Stanley upped their target price on shares of STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, STERIS currently has a consensus rating of “Moderate Buy” and an average price target of $273.50.

Insiders Place Their Bets

In other news, Director Cynthia L. Feldmann sold 3,495 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $241.56, for a total value of $844,252.20. Following the transaction, the director owned 705 shares of the company’s stock, valued at $170,299.80. This represents a 83.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Renato Tamaro sold 3,204 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $249.24, for a total value of $798,564.96. Following the transaction, the vice president directly owned 7,221 shares in the company, valued at $1,799,762.04. This trade represents a 30.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 18,868 shares of company stock valued at $4,585,389. 1.07% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of STE. Geneos Wealth Management Inc. boosted its holdings in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares during the last quarter. MUFG Securities EMEA plc bought a new position in STERIS in the 2nd quarter worth approximately $69,000. Peapack Gladstone Financial Corp bought a new stake in STERIS in the 2nd quarter valued at $200,000. Evergreen Capital Management LLC boosted its stake in STERIS by 11.8% during the second quarter. Evergreen Capital Management LLC now owns 1,005 shares of the medical equipment provider’s stock valued at $241,000 after buying an additional 106 shares during the last quarter. Finally, Voleon Capital Management LP bought a new stake in STERIS in the second quarter worth $263,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.